Introduction
Sphingosine-1-phosphate (S1P) and lysophosphatidic acid (LPA) are bioactive lysophospholipids that bind and signal through multiple G protein-coupled receptors (1) (2) (3) . Many physiological processes, such as cell growth, differentiation, survival, motility, angiogenesis (3) , and pathophysiological processes, such as cancer, cardiovascular disease, multiple sclerosis, neuropathic pain, and fibrosis (4, 5) involve S1P or LPA signaling. The S1P and LPA pathways are validated therapeutic targets; many drugs and pharmacological agents have been developed to modulate the activity of receptors and enzymes in these pathways (1, 4, 6) . Many of these compounds block circulating S1P and LPA from binding and activating cognate membrane-bound receptors.
Circulating S1P exists primarily bound to carrier molecules, including high-density and low-density lipoproteins and serum albumin. HDL is a protein-rich lipoprotein containing multiple protein constituents (7) and reportedly binds ~50-70% of plasma S1P, whereas serum albumin reportedly binds ~30% or more (8) (9) (10) . Apolipoprotein M (apoM) represents the main protein component in HDL responsible for binding S1P, and the x-ray co-crystal structure of recombinant human apoM in complex with S1P has been solved (11) . Human plasma contains approximately 0.9 µM apoM (11, 12) , where >95% of the total apoM occupies ~5% of the HDL (apoM-HDL) and <2% of the LDL (apoM-LDL) in plasma (13, 14) ; this stoichiometry results in less than 1 mole of S1P per mole of HDL in human plasma (15) . S1P-associated HDL stimulates cellular pathways that promote endothelial barrier function, suggesting S1P mediates the protective effects of HDL against atherosclerosis (16) . While S1P bound apoM-HDL suppresses vascular inflammation, S1P delivered using albumin did not show this effect in vitro, suggesting divergent roles for S1P chaperones in maintaining the vasculature and other physiological processes (17, 18) .
In blood, LPA also exists bound to carrier proteins, primarily serum albumin (19, 20) . Total LPA in plasma comprises several distinct species, which contain esterified fatty acids with varying numbers of carbon atoms and cis double bonds ( Figure 1A ) capable of activating cognate GPCRs with varying by guest, on www.jlr.org Downloaded from 5 potencies (21, 22) . Although albumin is the most abundant protein in human plasma and LPA is one of the first bioactive lipids identified, the stoichiometry and mechanism of interaction between these two molecules is poorly understood. As with fatty acids, serum albumin has the capacity to bind multiple LPA molecules per protein molecule (23) (24) (25) . Studies suggest albumin contains three, strong affinity, longchain fatty acid binding sites, and these are the same sites occupied by LPA (26, 27) .
The method described in this report uses monoclonal antibodies to compete with purified serum albumin or isolated lipoprotein particles for binding S1P and LPA in solution (see cartoon schematic in Figure 1B ). The production and characterization of the two humanized, IgG1k monoclonal antibodies, LT1009 and LT3015, which specifically recognize S1P and LPA, respectively, and the structural basis for lipid recognition are described elsewhere (28, 29) . These antibodies directly compete with carrier proteins for binding target lipids in vitro; the equilibrium binding curve for LT3015 binding LPA shifts towards weaker apparent affinity as the concentration of fatty-acid free bovine serum albumin is increased ( Figure   1C ). During competition binding, the equilibrium dissociation constants (K d ) for the antibody-lipid and protein-lipid interactions govern the concentration of antigen-free binding site on the antibody. Therefore, measuring the free antibody enables the K d for both the antibody (K d1 ) and the serum protein (K d2 ) binding S1P or LPA to be determined. 
Materials and Methods

Reagents and Lipid Preparations
The antigen-free binding sites on LT1009 and LT3015 were measured using a KinExA 3200 equipped with an autosampler. The antibody was captured using modified S1P and LPA, which contain a mercapto group covalently attached to the omega carbon atom and crosslinked to maleimide-activated BSA (Thermo Scientific) (3). The purified S1P-BSA and LPA-BSA conjugates were diluted (30 µg/mL) with PBS without calcium and magnesium (PBS, Cellgro), and 1 mL of the solution was added to 0.2 g of PMMA beads (Sapidyne Instruments). The slurry was rocked for 1 h at 37 ˚C to adsorb the conjugate onto the beads. After coating, the beads were blocked with 150 µM Fraction V FAF-BSA (Calbiochem)
in PBS. The concentrations of the protein stock solutions were determined by measuring the absorbance at 280 nm and using an extinction coefficient of 1.4 mL/mg for LT1009 and LT3015 and 0.66 mL/mg for FAF-BSA and FAF-HSA (Sigma-Aldrich) (38) (39) (40) (41) . (Echelon Biosciences) were re-suspended in methanol by repeated sonication and vortex mixing. The lysophospholipid concentration in each stock solution was determined using a colorimetric total phosphorus assay using a protocol from Avanti Polar Lipids, which was based on work by Chen et al. and
Fiske et al (42, 43) . Aliquots of the re-suspended lipid stocks were transferred to glass vials via a glass syringe and the solvent was evaporated under a dry argon stream.
Kinetic Exclusion Determination
In order to demonstrate the experiments described below were conducted in the so called "KinExA 
Serum Albumin Affinity Experiments
Dried aliquots of S1P were re-suspended in S1P running buffer (10 mM HEPES, 150 mM NaCl, 2.5 mM CaCl 2, 0.005% polysorbate 20, 0.02 NaN 3, pH 7.4) containing 100 µM FAF-BSA by sonication and vortex mixing to yield a 0.1 mM S1P stock solution. Calcium was included in the running buffer because divalent metal ions bridge the antibody-S1P interface and are required for strong affinity binding (28) . A series of 2-fold S1P dilutions were prepared in glass vials using a glass syringe using the running buffer was measured in duplicate, and the data were analyzed using drift correction in the competition n-curve software as detailed in Data Analysis Procedures below.
Data Analysis Procedures
The binding experiments described here involved a carrier protein (FAF-BSA, FAF-HSA, apoM-HDL, or apoM-LDL) in the reaction mixture. Generally, the K d for the binding of the lipid to the carrier protein is more than an order of magnitude weaker than the antibody binding, however experimental conditions often dictate the carrier protein be present at concentrations more than an order of magnitude higher than the antibody. This results in a situation where the antibody and carrier protein compete for the lipid, an effect which must be taken into account when measuring the K d values of the antibody-lipid and carrier protein-lipid interactions.
The mathematics of competitive binding is well known and both exact and implicit solutions to the fundamental equations of binding and conservation of mass have been described (44, 45) .
In the present case we implemented an implicit solution of the following set of equations
where K d1 and K d2 are the equilibrium binding constants of lipid (L) for antibody (Ab) and carrier protein (P), respectively. The final three equations express conservation of mass requirements for binding.
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In the present analyses, the total concentrations of the antibody, The most complicated cases analyzed involved LT1009 binding S1P in the presence of apoM-HDL or apoM-LDL. The complication here is that neither lipoprotein particle was available in a form that was both active as a chaperone protein and free of S1P. Consequently, adding apoM-HDL or apoM-LDL to an experimental mixture introduces an unknown quantity of S1P. For analysis, the presence of endogenous ligand was accommodated by adding a parameter to the model to express the fraction of the apoM carrying an S1P molecule. This parameter was varied to fit the data and evaluated for uniqueness by construction of an error graph.
Confidence intervals (C.I.) for the various parameters were constructed using a Monte Carlo method as described by Straume (46) . Briefly, the optimal fitted parameters were used to construct a noise free "data" set. Pseudo random noise was added to the simulated data and then analyzed for best fit parameters using the same algorithms used for analysis of the measured data. The magnitude of noise added was chosen such that the residual error at best fit was close to the residual for the corresponding measured data set. The addition of pseudo random noise and subsequent analysis was repeated one thousand times and 12 the resultant one thousand best fit values of the various parameters were recorded. The 95% C.I. was then taken as range from the 25 th smallest parameter value to the 25 th largest parameter value.
A molecular weight of 66 kDa for FAF-BSA and FAF-HSA was used for molarity calculations and was based on the manufacturer provided molecular weights. The total HDL and LDL protein concentration were determined using the bicinchoninic acid assay (HDL, 14.9 mg/mL; LDL, 6.56 mg/mL) and are in good agreement with concentrations provided by the manufacturer (HDL, 13.7 mg/mL; LDL, 6.39 mg/mL). ApoM concentration measurements were carried out in the lab of C.
Christoffersen by C. Wandel as previously described (36) . All data were exported to GraphPad Prism software for visualization (GraphPad Software, Inc.).
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Results
The competition binding between carrier proteins and monoclonal antibodies that specifically bind S1P and LPA has been investigated using KinExA Table 1 by guest, on www.jlr.org
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14 illustrates the effect of using FAF-BSA to deliver LPA in these types of equilibrium binding experiments.
Serum Albumin and LT3015 Binding the Major LPA Species
Serum albumin contains three high-affinity long-chain fatty acid binding sites (27, 47, 48) , which can be occupied by LPA (26) . Using this stoichiometry (3:1 LPA:albumin (49) Figure 2A ,C-E and Figure 3A ,C-E). For LPA(18:0), the upper 95% confidence interval is 93 pM for K d1 and 11 nM for K d2 , and the lower 95%
confidence interval is unresolved ( Figure 2B , 3B). We also analyzed these data using 2:1 and 1:1 LPA:albumin ratios (Supplemental Table 1 ). For 1:1 LPA:albumin, the K d2 value is precisely one-third the value reported in Table 1 , while the other parameters do not significantly change. This direct,
proportional relationship between the concentration of ligand binding sites on albumin and the K d2 value was observed for all LPA:albumin ratios analyzed.
In the competition n-curve analysis, K d2 is overwhelmingly based on the 10 µM albumin experiment (orange curve, Figure 2 ). Separate competition n-curve analyses using 10 µM FAF-HSA instead of FAF- (Table 1) and FAF-HSA (Table 2) suggests: 1) FAF-BSA and FAF-HSA bind each LPA species with similar affinities,
2) both FAF-BSA and FAF-HSA bind stronger (lower K d2 value) to fully saturated LPA species, and 3) as the number of double bonds in the LPA species increase, the affinity for serum albumin weakens (higher K d2 value).
In this analysis, the antibody concentration is used as a reference, which assumes the antibody preparation is fully active. The advantage of fixing the antibody concentration as the reference is that we could float a parameter that represents the amount of ligand (S1P or LPA) present in the sample sets as a 
Serum Albumin and LT1009 Binding S1P
We also investigated competition between the anti-S1P antibody, LT1009, and FAF-BSA for S1P binding using the same approach described for LPA above. A competition n-curve analysis of two 1 µM Figure S2F and 3F) for the S1P-HSA interaction.
ApoM-HDL and ApoM-LDL Binding S1P
As mentioned above, the total concentration of ligand binding sites for the chaperone protein must be defined to resolve the K d2 value using the competition n-curve analysis. To gain this information, the concentration of apoM in pooled human HDL and LDL preparations was measured using a published ELISA method (36) . The concentration of apoM in our human HDL and LDL preparations measured 21.0 µM and 0.83 µM, respectively, which equates to 1.41 µmol apoM/g total protein and 0.13 µmol apoM/g total protein for HDL and LDL, respectively.
Using these concentrations and 1:1 S1P:apoM stoichiometry, the K d values for S1P binding apoM-HDL and apoM-LDL, the ligand activity (percent nominal S1P concentration), and the concentrations of S1P in the HDL and LDL stock solutions were determined. Five equilibrium affinity experiments were used to resolve these parameters; 3 experiments maintained a fixed concentration of apoM-HDL or apoM-LDL while titrating exogenous S1P ( and 430 pM (95% C.I. 370-510 pM), respectively. These K d1 values for S1P-LT1009 interactions determined from the apoM-HDL/LDL analysis are in good agreement with the values determined when S1P is delivered using FAF-BSA/HSA (Tables 1 and 2 ). The activity of the titrated S1P was 74% (95% C.I. 57-103%) and 83% (95% C.I. 69-99%) for apoM-HDL and apoM-LDL experiments, respectively, which is also similar to the percent S1P activity in the FAF-BSA/HSA experiments.
The concentration of endogenous S1P in the HDL and LDL preparations was calculated using a parameter that represents the S1P concentration in the stock solutions as a fraction of the total S1P binding sites on the chaperone, or the total apoM concentration in this analysis. The multiplier value was determined to be 0.10 (95% C.I. 0.096-0.11) and 0.25 (95% C.I. 0.22-0.28) for apoM-HDL and apoM-LDL, respectively, which calculates to 2.1 M and 0.21 M S1P in the HDL and LDL preparations, respectively. By comparison, the total S1P (S1P+dihydroS1P) in these preparation measured 1.7 M and 0.11 M, respectively, using HPLC-MS/MS. The S1P content in these HDL and LDL preparations respectively. These levels are consistent with previous reports describing the S1P content in analogous lipoprotein preparations (51, 52).
Lipids other than S1P, such as myristic acid and oxidized phospholipids, have been reported to associate with apoM (13). In order to address the effect of additional lipids competing with S1P for binding apoM, we carried out a series of simulations using our data and introducing an additional lipid and K d . For this work, we expanded the model to include a second lipid that competes with S1P for apoM binding sites but does not bind to the antibody. Here, again, we looked for uniqueness of fit by calculating error curves as described above. We were not able to determine from this work whether there was additional lipid present on the apoM or not, however, our fitting of the model to the data suggests that any lipid present is not significantly affecting the binding. We were able to find fits equivalent to the simpler In order to determine K d2 using this method, the number of ligand binding sites on the carrier protein must be assigned. Thumser et al. reports three moles of LPA could bind to one mole of serum albumin (26) , and likely occupy the same three high affinity sites as long-chain fatty acids (27, 48) . Based on these reports, we performed the competition n-curve analysis using three LPA binding sites per albumin molecule (3:1 LPA:albumin). We also analyzed the data using stoichiometries ranging from one to six, and in every case the number of LPA binding sites on serum albumin directly and proportionally modulates the K d2 value for the interaction. For example, the K d2 for FAF-BSA binding LPA (16:0) reported in Table 1 to the lack of published data on the S1P:albumin stoichiometry, one S1P-binding site per serum albumin molecule was used for this analysis.
The equilibrium binding of serum albumin to LPA has been studied previously. Goetzl et al. reported a K d of 357 ± 64 nM for FAF-BSA binding LPA using a radiometric equilibrium binding assay (34) .
Although the authors did not specify which LPA species was used, we speculate it was LPA (18: Tables 1 and 2 are all in the hundreds of nanomolar (10 -7 M) range. In addition, Ojala et al. report an apparent K d for HSA binding S1P of 1.3 µM, which is somewhat stronger than the K d2 value of 22 µM we report in Table 2 .
The competition binding analysis performed here suggests the affinity of LT3015 is 10 2 -10 3 times stronger than the affinity of serum albumin for these individual LPA species. Interestingly, both the K d1
and K d2 values for LT3015 and serum albumin binding LPA(20:4) are significantly weaker compared to the other LPA species tested (Table 1 and Table 2 ). The weaker affinity of LT3015 for LPA(20:4) may be due to the C5-C6 cis double bond in the acyl chain of LPA(20:4), which is not present in the other LPA species ( Figure 1A) . Based on the LT3015 Fab-LPA(14:0) and Fab-LPA(18:2) crystal structures, the LPA epitope consists of the glycerolphosphate group plus the juxtaposed C1-C8 carbon atoms of the acyl chain (29) . As visualized in both co-crystal structures, this portion of the bound LPA hydrocarbon chain is fully The distribution of S1P among serum proteins (HDL, LDL and HSA) in human plasma has been investigated. Most reports cite ~60-70% of plasma S1P associates with HDL and ~30% associates with HSA. By solving simultaneous equations using the K d2 values reported here and previously reported normal plasma concentrations (0.1-0.4 M S1P (58), 0.53-0.76 mM HSA (25), 0.6-1.3 M apoM-HDL (11, 12) , and 0.01-0.04 M apoM-LDL, which is 2% of total serum LDL particle concentration (59, 60),) the calculated S1P distribution ranges from 25-59% HSA bound, 35-68% apoM-HDL bound, and 1.6-16% bound to apoM-LDL. If the S1P concentration is increased to 1.2 M, the percent of S1P associated with apoM-HDL and apoM-LDL decreases, while the percent of S1P bound to albumin increases to 70% (Supplemental Table 2 ). This demonstrates how normal variability in plasma S1P and chaperone concentrations profoundly effects the S1P distribution among these carrier proteins. In addition, the fraction of each chaperone protein (as percent of total) associated with S1P at these concentrations is shown in Supplemental Table 3 . These data suggests normal plasma levels of apoM-LDL are nearly completely bound at 1.2 M S1P. The lipoprotein preparations used in this study were collected from a single, normal, male donor. Therefore, the inter-individual variation in K d2 values, which also influences the percent distribution of S1P, cannot be addressed but will be the focus of future investigations.
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Recent reports suggest S1P exhibits distinct biological effects depending on its chaperone protein (17, 18) . Wilkerson et al. demonstrated that S1P bound to apoM-HDL sustains the barrier function of human endothelial cells longer than S1P delivered using albumin (61) . In addition, the rate of S1P 1 receptor internalization and degradation in these cells is slower when S1P is complexed with HDL than with FAF-BSA. These observations are consistent with S1P having a relatively weak affinity for serum albumin, which likely poorly buffers S1P from receptor binding and internalization. Unlike albumin, our results suggest S1P has a relatively strong affinity for apoM-LDL. One proposed mechanism for S1P and apoM clearance from circulation involves the LDL receptor (52, 62). Kurano et al. demonstrated that overexpressing the LDL receptor results in lower plasma S1P and apoM concentrations in mice, and exogenous C 17 S1P is cleared more quickly in vivo and in vitro when the LDL receptor is overexpressed.
Here, we measured ~10-fold stronger affinity of S1P for apoM-LDL than apoM-HDL, which would be consistent with LDL-associated S1P targeted for clearance, while HDL-bound S1P bioavailable for receptor binding and activation. However, the role HDL plays in S1P-mediated biological processes is not necessarily consistent with that of 'free S1P.' In fact, sometimes it is contrary (63), suggesting a more intricate role for HDL in S1P-mediated receptor activation and signaling than solely direct competition with the S1P receptors.
Despite their relatively uncomplicated chemical structure, lipid recognition is notoriously difficult to study because the mechanisms of protein-lipid binding are often complex and unique physical properties of lipids bear particular experimental challenges. In recent years, modifying lipids with molecular tags and/or covalently attaching lipids to solid surfaces to study protein-lipid interactions has gained popularity (64, 65) . While these approaches may be acceptable for identifying novel lipid-binding proteins, qualitatively evaluating proteins binding to vesicles, or investigating membrane fluidity, these modifications may significantly alter the natural mode of lipid recognition. Therefore, we developed a method using anti-lipid monoclonal antibodies and KinExA to measure the equilibrium dissociation constants for two native lysophospholipids, S1P and LPA, binding several serum proteins in solution.
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In conclusion, individual LPA species bind albumin with a range of affinities, where shorter, fully saturated fatty acyl species demonstrate stronger affinity for albumin than polyunsaturated species. S1P exhibits a relatively weak affinity for serum albumin compared to apoM-HDL and apoM-LDL, where apoM-LDL represents the stronger affinity, lower capacity S1P carrier and HDL represents the moderate affinity, higher capacity S1P chaperone by comparison. These affinity measurements provide insights in to the role of these serum proteins in S1P and LPA transport and storage in circulation. a Anti-LPA, LT3015; anti-S1P, LT1009. 
